Quoin Pharmaceuticals Doses First Patient in Rare Disease Trial
Quoin Pharmaceuticals (Nasdaq:QNRX), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases has dosed the first patient in a clinical trial evaluating a treatment for Netherton Syndrome.
The company has announced it will initiate a second study assessing its QRX003 topical lotion in Netherton patients who are currently receiving off-label treatment including systemic therapy for symptomatic relief. This second study has now been cleared by the FDA to initiate clinical testing.
- Quoin’s six target clinical sites are on track to be fully opened by year end.
- More than 70 potential clinical trial candidates have already progressed through the company’s initial screening process.
- Second study evaluating QRX003 for Netherton Syndrome has been cleared by the FDA. The study will evaluate 10 Netherton patients over a 12-week period.
- Quoin believes that QRX003 has the potential to become the standard of care for Netherton patients.
To find out more about Quoin’s clinical trial, please visit: https://www.nethertonsyndromeclinicaltrials.com.